Evgen Pharma PLC Erasmus Medical Center begins glioblastoma studies
26 Oktober 2023 - 8:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
26 October 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Erasmus Medical Center commences SFX-01 Glioblastoma studies
Alderley Park, UK - 26 October 2023 : Evgen Pharma plc (AIM:
EVG), the clinical stage drug development company developing
sulforaphane-based medicines for the treatment of multiple diseases
and Dr Marjolein Geurts, neuro-oncologist at the Erasmus University
Medical Center, announce the formal start of their collaborative
project in glioblastoma, supported with a grant awarded by the KWF
Dutch Cancer Society. The grant start conditions and documentation
have been satisfied and the project formally commenced on 1
October.
The studies, which are funded by a grant towards total project
costs of approx. EUR 1.1m awarded by the KWF Dutch Cancer Society,
will investigate the use of SFX-01 in pre-clinical glioblastoma
models, followed by a clinical Investigator Sponsored Study (ISS),
aiming to establish the presence of the drug in human brain tumours
and engagement with relevant molecular targets in excised tumour
tissue.
The Erasmus University Medical Center team has also appointed a
dedicated, grant funded PhD student, who starts in early November.
The project is being carried out in the laboratory and clinic of Dr
Marjolein Geurts, neuro-oncologist at Erasmus Medical Center,
Cancer Institute, Rotterdam, in the Netherlands and will run for
three years, generating data continuously throughout the
period.
Although classed as a rare disease, cases of glioblastoma are
increasing, partly due to improvements in diagnoses and growth of
an ever-ageing population. Standard of care for glioblastoma
patients is surgery, radiotherapy and chemotherapy, however it is
still a disease of significant high unmet need where patient
survival rates from diagnosis are between 1 and 3 years and new
effective treatment options are sorely needed.
Dr Huw Jones, CEO of Evgen Pharma said:
"Commencing this study is a significant step in determining the
potential of SFX-01 as a therapeutic option for glioblastoma
patients. Previous preclinical studies with SFX-01 on Glioblastoma
have been striking so we look forward to this further validation
and entry into the clinic in due course."
Dr Marjolein Geurts, Erasmus University Medical Center
added:
"We are delighted to be working with Evgen Pharma on this
important project and hope that we will together find a new option
for patients with this disease who have few treatment options
currently."
Name change of Nominated Adviser and Broker
The Company also announces that its Nominated Adviser ("NOMAD")
and Broker finnCap Ltd, has changed its name to Cavendish Capital
Markets Limited.
-Ends-
Enquiries:
Evgen Pharma plc +44 207 457 2020
Dr Huw Jones, CEO enquiries@evgen.com
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish Capital Markets (N
OMAD and Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Nigel Birks (ECM) +44 20 7220 0500
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com
/Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. Recently, Evgen completed an out-licensing transaction
with Stalicla SA, a Swiss specialist company in neurodevelopmental
disorders, commencing with autism spectrum disorder. The deal, if
successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLBDGCXDDGXU
(END) Dow Jones Newswires
October 26, 2023 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
Von Jun 2023 bis Jun 2024